| Host |
Mouse |
| Klon |
3A4 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2a |
| Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
1 ml |
Concentrate |
RUO |
MOB318 |
-
|
| Host |
Mouse |
| Klon |
3A4 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2a |
| Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
0.1 ml |
Concentrate |
RUO |
MOB318-01 |
-
|
| Host |
Mouse |
| Klon |
3A4 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2a |
| Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
0.5 ml |
Concentrate |
RUO |
MOB318-05 |
-
|
| Host |
Mouse |
| Klon |
3A4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG2a |
| Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
6 ml |
Ready-to-use |
RUO |
PDM318 |
-
|
| Host |
Mouse |
| Klon |
3A4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG2a |
| Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
25 ml |
Ready-to-use |
RUO |
PDM318-25 |
-
|
| Host |
Mouse |
| Klon |
TF9-10H10 |
| Format |
Purified |
| Methode |
F, P, IF, EL, WB, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Purified apoprotein of human tissue factor |
Tissue Factor
|
Zytomed Systems GmbH |
TF9-10H10 |
100 µg |
Purified |
RUO |
620-0128 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM93 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Synovial sarcoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant human TLE1 fragment (aa 175-338) |
| Lokalisation |
Cytoplasm |
TLE1
|
Zeta Corporation |
ZM93 |
1 ml |
Concentrate |
CE/IVD |
Z2403ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM93 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Synovial sarcoma. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant human TLE1 fragment (aa 175-338) |
| Lokalisation |
Cytoplasm |
TLE1
|
Zeta Corporation |
ZM93 |
7 ml |
Ready-to-use |
CE/IVD |
Z2403MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM93 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Synovial sarcoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant human TLE1 fragment (aa 175-338) |
| Lokalisation |
Cytoplasm |
TLE1
|
Zeta Corporation |
ZM93 |
0.5 ml |
Concentrate |
CE/IVD |
Z2403MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM93 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Synovial sarcoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant human TLE1 fragment (aa 175-338) |
| Lokalisation |
Cytoplasm |
TLE1
|
Zeta Corporation |
ZM93 |
0.1 ml |
Concentrate |
CE/IVD |
Z2403MT |
-
|
| Host |
Mouse |
| Klon |
DBM15.28 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Histiocytoma, colon, pancreas |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgM kappa |
| Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
1 ml |
Concentrate |
CE/IVD |
MOB502 |
-
|
| Host |
Mouse |
| Klon |
DBM15.28 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Histiocytoma, colon, pancreas |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgM kappa |
| Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
0.1 ml |
Concentrate |
CE/IVD |
MOB502-01 |
-
|
| Host |
Mouse |
| Klon |
DBM15.28 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Histiocytoma, colon, pancreas |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgM kappa |
| Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
0.5 ml |
Concentrate |
CE/IVD |
MOB502-05 |
-
|
| Host |
Mouse |
| Klon |
DBM15.28 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Histiocytoma, colon, pancreas |
| Verdünnung |
- |
| Isotyp |
IgM kappa |
| Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
6 ml |
Ready-to-use |
CE/IVD |
PDM230 |
-
|
| Host |
Mouse |
| Klon |
DBM15.28 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Histiocytoma, colon, pancreas |
| Verdünnung |
- |
| Isotyp |
IgM kappa |
| Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
25 ml |
Ready-to-use |
CE/IVD |
PDM230-25 |
-
|
| Host |
Mouse |
| Klon |
31 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Cervix, tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human Topo Iiα aa 1245-1361 |
| Lokalisation |
Nuclear |
Topoisomerase II alpha
|
Biocare Medical |
31 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3045A |
-
|
| Host |
Mouse |
| Klon |
31 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Cervix, tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human Topo Iiα aa 1245-1361 |
| Lokalisation |
Nuclear |
Topoisomerase II alpha
|
Biocare Medical |
31 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3045B |
-
|
| Host |
Mouse |
| Klon |
31 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Cervix, tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human Topo Iiα aa 1245-1361 |
| Lokalisation |
Nuclear |
Topoisomerase II alpha
|
Biocare Medical |
31 |
6 ml |
Ready-to-use |
CE/IVD |
API3045AA |
-
|
| Host |
Goat |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
IF |
| Isotyp |
Goat IgG |
| Verdünnung |
RH strain of Toxoplasma Gondii |
Toxoplasma gondii
|
Zytomed Systems GmbH |
polyclonal |
1 mg |
Purified |
RUO |
620-0203 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P, F |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Infected tissue |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
IgG |
| Lokalisation |
Cell wall |
Toxoplasma gondii
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK068-05 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM174 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Hairy cell leukemia. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human ACP5 protein |
| Lokalisation |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
1 ml |
Concentrate |
CE/IVD |
Z2486ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM174 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Hairy cell leukemia. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human ACP5 protein |
| Lokalisation |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
7 ml |
Ready-to-use |
CE/IVD |
Z2486MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM174 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Hairy cell leukemia. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human ACP5 protein |
| Lokalisation |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
0.5 ml |
Concentrate |
CE/IVD |
Z2486MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM174 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Hairy cell leukemia. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human ACP5 protein |
| Lokalisation |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
0.1 ml |
Concentrate |
CE/IVD |
Z2486MT |
-
|
| Host |
Rabbit |
| Klon |
ZR243 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Lokalisation |
cell membrane |
TRAcP
|
Zeta Corporation |
ZR243 |
0.1 ml |
Concentrate |
CE/IVD |
Z2714RT |
-
|
| Host |
Mouse |
| Klon |
5G63 |
| Format |
Culture Supernatant |
| Methode |
IHC(P) |
| Vorbehandlung |
Citrat pH 6.0 |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
mouse |
Transferrin Receptor (CD71)
|
Zytomed Systems GmbH |
5G63 |
500 µL |
Culture Supernatant |
RUO |
103-2299 |
-
|
| Host |
Mouse |
| Klon |
TB21 |
| Format |
Purified |
| Methode |
F, P, EL |
| Positivkontrolle |
Human breast carcinoma |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human transforming groth factor beta 1 from platelets |
Transforming Growth Factor beta (TGFb)
|
Zytomed Systems GmbH |
TB21 |
100 µg |
Purified |
RUO |
620-0255 |
-
|
| Host |
Mouse |
| Klon |
TB21 |
| Format |
Purified |
| Methode |
F, P |
| Positivkontrolle |
Human breast carcinoma |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human transforming groth factor beta 1 from platelets |
Transforming Growth Factor beta (TGFb)
|
Zytomed Systems GmbH |
TB21 |
10 µg |
Purified |
RUO |
620-0256 |
-
|
| Host |
Mouse |
| Klon |
CUB7402 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
1 ml |
Concentrate |
CE/IVD |
MOB353 |
-
|
| Host |
Mouse |
| Klon |
CUB7402 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
0.1 ml |
Concentrate |
CE/IVD |
MOB353-01 |
-
|
| Host |
Mouse |
| Klon |
CUB7402 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
0.5 ml |
Concentrate |
CE/IVD |
MOB353-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
ER1 |
| Positivkontrolle |
Lymphoma, Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane |
TRBC1
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3280G7 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Lymphoma, Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane |
TRBC1
|
|
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
AVI3280G |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
P, IF |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
infected tissue |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Native, purified |
Treponema pallidum
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
620-0262 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Verdünnung |
1:100 - 1:200 |
| Verdünnung |
Treponema pallidum |
| Lokalisation |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
1ml |
Concentrate |
RUO |
Z2554RL-R |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Verdünnung |
- |
| Verdünnung |
Treponema pallidum |
| Lokalisation |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
RUO |
Z2554RP-R |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Verdünnung |
1:100 - 1:200 |
| Verdünnung |
Treponema pallidum |
| Lokalisation |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
RUO |
Z2554RS-R |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Verdünnung |
1:100 - 1:200 |
| Verdünnung |
Treponema pallidum |
| Lokalisation |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
RUO |
Z2554RT-R |
-
|
| Host |
Mouse |
| Klon |
1306/156 |
| Format |
Purified |
| Methode |
EL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Native |
Trichomonas vaginalis (Strain 1)
|
Zytomed Systems GmbH |
1306/156 |
200 µg |
Purified |
RUO |
620-0265 |
-
|
| Host |
Rabbit |
| Klon |
EPR17341 |
| Format |
Concentrate |
| Methode |
P, IF, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Astrocytoma, cerebral cortex tissue |
| Verdünnung |
1:500 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus. The exact sequence is proprietary. |
| Lokalisation |
Cytoplasm |
TrkA + TrkB + TrkC
|
Abcam |
EPR17341 |
0.1 ml |
Concentrate |
RUO |
AB181560 |
-
|
| Host |
Rabbit |
| Klon |
SP293 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P, WB, FL |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human TROP-2 protein |
| Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP293 |
0.5 ml |
Concentrate |
RUO |
520-5932 |
-
|
| Host |
Rabbit |
| Klon |
SP293 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P, WB, FL |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human TROP-2 protein |
| Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP293 |
1 ml |
Concentrate |
RUO |
520-5934 |
-
|
| Host |
Rabbit |
| Klon |
SP294 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
| Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP294 |
0.5 ml |
Concentrate |
RUO |
520-5942 |
-
|
| Host |
Rabbit |
| Klon |
SP294 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
| Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP294 |
1 ml |
Concentrate |
RUO |
520-5944 |
-
|
| Host |
Rabbit |
| Klon |
SP295 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
| Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP295 |
0.5 ml |
Concentrate |
RUO |
520-5952 |
-
|
| Host |
Rabbit |
| Klon |
SP295 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
| Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP295 |
1 ml |
Concentrate |
RUO |
520-5954 |
-
|
| Host |
Rabbit |
| Klon |
ZR388 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast or colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
| Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
1 ml |
Concentrate |
CE/IVD |
Z2744RL |
-
|
| Host |
Rabbit |
| Klon |
ZR388 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast or colon carcinoma |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
| Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
7 ml |
ready-to-use |
CE/IVD |
Z2744RP |
-
|
| Host |
Rabbit |
| Klon |
ZR388 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast or colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
| Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
0.5 ml |
Concentrate |
CE/IVD |
Z2744RS |
-
|
| Host |
Rabbit |
| Klon |
ZR388 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast or colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
| Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
0.1 ml |
Concentrate |
CE/IVD |
Z2744RT |
-
|